SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 6073-6082

  Liu, Chunhua ^a   Shi, Xuefei ^a   Wang, Li ^a   Wu, Ying ^a   Jin, Feiyan ^b   Bai, Cuiqing ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; NSCLC; Proliferation; SUZ12

Indexed keywords

POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; ROUNDABOUT HOMOLOG 1 PROTEIN; SMALL INTERFERING RNA; SUPPRESSOR OF ZESTE 12 PROTEIN; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84904726416     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1804-5     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. doi:10.3322/caac.20006.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi:10.3322/caac.21166.
3. Wu YL, Zhou Q. Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets. 2012;16 Suppl 1:S45-50. doi:10.1517/14728222. 2011.630663.
4. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics. 2013;6:53. doi:10.1186/1755-8794-6-53.
5. Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer - genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2013;157(2):125-36. doi:10.5507/bp.2013.034.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80. doi:10.1056/NEJMra0802714.
7. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(24):3316-21. doi:10.1200/jco.2010.33.3757.
8. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441(7091):349-53. doi:10.1038/nature04733. (Pubitemid 44050199)
9. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (New York, NY). 2002;298(5595):1039-43. doi:10.1126/science.1076997. (Pubitemid 35247314)
10. Koyanagi M, Baguet A, Martens J, Margueron R, Jenuwein T, Bix M. EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem. 2005;280(36):31470-7. doi:10.1074/jbc.M504766200. (Pubitemid 41291889)
11. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004;23(20):4061-71. doi:10.1038/sj.emboj.7600402. (Pubitemid 39472427)
12. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-4. doi:10.1038/nature04431. (Pubitemid 43255707)
13. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28(15):4772-81. doi:10.1128/mcb.00323- 08.
14. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761-72. doi:10.1016/j.molcel.2010.08.013.
15. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer cell. 2007;11(6):513-25. doi:10.1016/j.ccr.2007.04.009. (Pubitemid 46863505)
16. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(2):268-73. doi:10.1200/jco.2005.01.5180. (Pubitemid 46622055)
17. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 2007;67(5):547-56. doi:10.1002/pros.20550. (Pubitemid 46536947)
18. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606-11. doi:10.1073/pnas.1933744100. (Pubitemid 37205983)
19. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosom Cancer. 2006;45(7):639-45. doi:10.1002/gcc.20327. (Pubitemid 43727151)
20. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624-9. doi:10.1038/nature01075.
21. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012;10(11):1462-72. doi:10.1158/1541-7786.mcr-12-0335.
22. Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, et al. Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol. 2010;177(2):930-42. doi:10.2353/ajpath.2010.090769.
23. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer cell. 2008;13(1):11-22. doi:10.1016/j.ccr.2007.11.031. (Pubitemid 350309738)
24. Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E, et al. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics. 1995;25(1):130-8.
25. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999;81(4):535-8. (Pubitemid 29203048)
26. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 2000;9(4):395-401. (Pubitemid 30265783)
27. Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006;16(7):890-900. doi:10.1101/gr.5306606. (Pubitemid 43992913)
28. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, et al. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol. 2008;61(5):601-5. doi:10.1136/jcp.2007.050963. (Pubitemid 351678211)
29. Kwong RA, Nguyen TV, Bova RJ, Kench JG, Cole IE, Musgrove EA, et al. Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(10 Pt 1):3705-11. (Pubitemid 37169239)
30. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(1):82-8. doi:10.1158/1078-0432.ccr-07-0612. (Pubitemid 351409260)
31. Moller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 2000;14(5):898-904. (Pubitemid 30235069)
32. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst. 1999;91(10):874-81. (Pubitemid 29252304)
33. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol. 2002;198(2):157-62. doi:10.1002/path.1185. (Pubitemid 35243873)
34. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(23):6938-46. doi:10.1158/1078-0432.ccr- 07-1539. (Pubitemid 350276873)
35. Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A. 2014;111(3):E384-93. doi:10.1073/pnas.1321510111.
36. Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, et al. MicroRNA 135a Suppresses lymph node metastasis through downregulation of ROCK1 in early gastric cancer. PloS One. 2014;9(1):e85205. doi:10.1371/journal.pone.0085205.
37. Wang J, Liu XH, Yang ZJ, Xie B, Zhong YS. The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer. 2014;14(1):89. doi:10.1186/1471-2407-14-89.
38. Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2013. doi:10.1038/onc.2013.505.
39. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67(2):171-7. doi:10.1007/s00018-009-0189-x.
40. Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol. 2008;33(3):585-93.
41. Lin SL, Chang D, Ying SY. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis. 2007;28(2):310-20. doi:10.1093/carcin/bgl134. (Pubitemid 46321846)
42. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742-51. doi:10.1158/0008-5472.can-09-1541.
43. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010;29(17):2591-8. doi:10.1038/onc.2010.3.
44. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1-2):65-76. doi:10.1007/s10555-008-9170-7.
45. Guan H, Zu G, Xie Y, Tang H, Johnson M, Xu X, et al. Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J Immunol (Baltimore, Md : 1950). 2003;171(12):6519-26.
46. Bhat KM, Gaziova I, Krishnan S. Regulation of axon guidance by slit and netrin signaling in the Drosophila ventral nerve cord. Genetics. 2007;176(4):2235-46. doi:10.1534/genetics.107.075085. (Pubitemid 47360656)
47. Dickson BJ, Gilestro GF. Regulation of commissural axon pathfinding by slit and its Robo receptors. Annu Rev Cell Dev Biol. 2006;22:651-75. doi:10.1146/annurev.cellbio.21.090704.151234.
48. Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, Goodman CS, et al. Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell. 1998;92(2):205-15. (Pubitemid 28073044)
49. Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, Roy A, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122(1):71-81. doi:10.1007/s00439-007-0375-6. (Pubitemid 47040575)
50. Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer. 2006;5:16. doi:10.1186/1476-4598-5-16.
51. Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK. Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem. 2008;283(39):26624-33. doi:10.1074/jbc.M800679200.